Kidney toxicity of the BRAF-kinase inhibitor vemurafenib is driven by off-target ferrochelatase inhibition
Yuntao Bai, JY Kim, Bijay Bisunke, Laura A. Jayne, Josie A. Silvaroli, Michael S. Balzer, Megha Gandhi, Kevin M. Huang, Veronika Sander, Jason Prosek, Rachel E. Cianciolo, Sharyn D. Baker, Alex Sparreboom, Kenar D. Jhaveri, Katalin Suszták, Amandeep Bajwa, Navjotsingh Pabla
Topics & Concepts
VemurafenibFerrochelataseKidneyCancer researchMedicineAcute kidney injuryBiologyInternal medicineMelanomaEnzymeHemeBiochemistryMetastatic melanomaMelanoma and MAPK PathwaysCell death mechanisms and regulationCancer-related Molecular Pathways